secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0000950170-22-015582
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clearside Biomedical enters royalty financing with HealthCare Royalty for up to $65M
--------------------------------------------------------------------------------

- Upfront cash of $32.5M; additional $12.5M escrow tied to XIPERE sales milestone, plus up to $20M second milestone.
- HealthCare Royalty receives royalties from XIPERE and SCS Microinjector license deals until 2.5x (or 3.4x) payback achieved.
- Proceeds intended to support CLS-AX (axitinib injectable suspension) clinical program via suprachoroidal injection.
- Deal excludes Clearside's internal pipeline and future in-licensed assets; non-dilutive capital.
- Transaction expected to close in August 2022; JMP Securities acted as financial advisor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017022015582/0000950170-22-015582-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017022015582/clsd-20220808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-015582

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer